Verantos and CuriMeta collaborate to strengthen real-world evidence generation

Verantos and CuriMeta partner to expand access to high-quality real-world data for life sciences research.

Verantos, an artificial intelligence (AI)-powered real-world evidence (RWE) provider, has partnered with CuriMeta to expand the availability of health data for research. Through this collaboration, CuriMeta will contribute de-identified data from 7 million patients, enhancing the quality and diversity of real-world data (RWD) accessible to life sciences organizations. Initial collaborators for CuriMeta include BJC HealthCare and Washington University School of Medicine in St. Louis.

CuriMeta partners with healthcare organizations to collect, process, and share real-world health data with researchers. This allows researchers to gain insights that can address scientific and clinical issues, with the goal of improving patient outcomes across different medical fields.

CuriMeta’s objective is to enable research and the development of new diagnostics and therapeutics by connecting leading health systems and academic medical centers with life sciences organizations. CEO Davis Walp emphasized that for complex therapies to be accepted by regulators, providers, and patients, robust evidence and clinical value are essential, saying,

“Complex therapies necessitate providing more robust evidence and greater clinical value to achieve acceptance by regulators, providers, and patients. Our partnership with Verantos will help connect patients with lifesaving therapies in the future.”

The Verantos Research Network is a distributed collection of healthcare organizations, including academic and community health systems, claims sources, and registries, which aims to provide access to robust RWD.

Anand Shroff, President of Verantos, highlighted the importance of using high-quality patient care data to train AI models for generating disease-specific insights through the Verantos Evidence Platform. He stated, “It is critical that AI models are trained using high-quality patient care data. CuriMeta’s participation will enable us to enhance our disease-specific Pragmatic Registries that are used to accelerate life sciences research.”

The collaboration between Verantos and CuriMeta will span across therapeutic areas, with CuriMeta’s data supporting various disease-specific Pragmatic Registries within Verantos’ portfolio.